Early Versus Late Assessment of Stroke Outcome

Stroke

Volumn 47, Issue 5, 2016, Pages 1416-1419

  Lees, Kennedy R ^a   Selim, Magdy H ^c   Molina, Carlos A ^d   Broderick, Joseph P ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF CINCINNATI   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

follow up studies; outcome; risk factors; stroke; time

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CRANIECTOMY; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOVASCULAR SURGERY; FOLLOW UP; HEALTH ECONOMICS; HEMICRANIECTOMY; HUMAN; IMMOBILITY; MINIMALLY INVASIVE SURGERY; NATIONAL HEALTH ORGANIZATION; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANKIN SCALE; SUBARACHNOID HEMORRHAGE; SURVIVAL; SURVIVOR; THROMBECTOMY; AGED; BIOASSAY; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DECOMPRESSION; ISCHEMIC STROKE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; RISK FACTOR; SAMPLE SIZE; STROKE SURVIVOR;

AGED; EARLY DIAGNOSIS; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84959139121     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011153     Document Type: Note

References (15)

1. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833. doi: 10.1161/STROKEAHA.109.561365.
2. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP, et al; DECIMAL Investigators. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL trial). Stroke. 2007;38:2506-2517. doi: 10.1161/STROKEAHA.107.485235.
3. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
4. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
5. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al; European Stroke Organization Outcomes Working Group. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012;43:1163-1170. doi: 10.1161/STROKEAHA.111.641423.
6. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014; 379: 2352-2363. doi: 10.1016/S0140-6736(14)60584-5.
7. MacIsaac RL, Khatri P, Bendszus M, Bracard S, Broderick J, Campbell B, et al; VISTA Endovascular Collaboration. A collaborative sequential metaanalysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential metaanalysis performed within the VISTA-Endovascular collaboration. Int J Stroke. 2015;10(suppl A100):136-144. doi: 10.1111/ijs.12622.
8. Palesch YY, Yeatts SD, Tomsick TA, Foster LD, Demchuk AM, Khatri P, et al; Interventional Management of Stroke III Investigators. Twelvemonth clinical and quality-of-life outcomes in the Interventional Management of Stroke III trial. Stroke. 2015;46:1321-1327. doi: 10.1161/STROKEAHA.115.009180.
9. MISTIE II results. American Heart Association website: https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-436205.pdf. Accessed November 24, 2015.
10. MISTIE II: 365-day results demonstrate improved outcome and cost benefit. American Heart Association website: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-449049.pdf. Accessed November 24, 2015.
11. Wilson DA, Nakaji P, Albuquerque FC, McDougall CG, Zabramski JM, Spetzler RF. Time course of recovery following poor-grade SAH: the incidence of delayed improvement and implications for SAH outcome study design. J Neurosurg. 2013;119:606-612. doi: 10.3171/2013.4.JNS121287.
12. Kong KH, Lee J. Temporal recovery and predictors of upper limb dexterity in the first year of stroke: a prospective study of patients admitted to a rehabilitation centre. Neuro Rehabilitation. 2013;32:345-350. doi: 10.3233/NRE-130854.
13. Kwiatkowski T, Libman R, Frankel M, Tilley B, Morganstern L, et al; NINDS rt-PA Stroke Study Group. The NINDS rt-PA stroke study: sustained benefit at one year. Stroke. 1998; 29:288.
14. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-890.
15. Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015;46:2591-2598. doi: 10.1161/STROKEAHA.115.009396.